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Study shows that caffeine does not cause 
arrhythmia in patients with heart failure  
In a study conducted at Hospital de Clínicas in Porto Alegre, researchers 
tested the short-term effects of high-dose caffeine  
Author: Camila Raposo 
Researchers from UFRGS and Hospital de Clínicas de Porto Alegre (HCPA) have 
demonstrated from clinical trials that the consumption of high doses of caffeine 
does not cause arrhythmia in heart failure patients. The results of the study, 
published in the journal Jama Internal Medicine, challenge the prevailing 
recommendation that people with heart problems should limit their caffeine intake. 
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The study included 51 patients recruited at HCPA. Before the trials began, 
participants were instructed not to consume any food or drink that contained 
caffeine for seven consecutive days. After this period, they were divided into two 
groups. The first one received five 100 ml doses of decaffeinated coffee mixed with 
100 mg of caffeine each, totaling 500 mg of the substance (equivalent to five cups 
of 150 ml coffee approximately), while the control group received doses of 
decaffeinated coffee mixed with lactose. The doses were consumed at intervals of 
one hour, with continuous monitoring by means of electrocardiogram. One hour 
after the last dose, patients were subjected to a treadmill stress test to assess 
whether caffeine could pose a risk of physical exercise. The procedures were 
performed at the HCPA Clinical Research Center. 
After this stage, the patients spent seven more days without caffeine intake and 
returned to the hospital for the second stage of testing. At that time, the same 
protocol was maintained, but the groups were reversed – those in the control group 
started to consume caffeine, and those who ingested caffeine previously consumed 
the placebos. "In this methodological model, we have, for the same subject and for 
the same metabolism, the reaction of the two stages, intervention and placebo", 
explains the doctoral student of the Graduate Program in Cardiology at UFRGS, 
Priccila Zuchinali, who is one of the authors of the study. 
At first, for safety reasons, only patients with an implantable cardioverter 
defibrillator (ICD) – a small device implanted under the skin that can detect 
anomalies in the heart rhythm and revert them by electric pulses – participated in 
the study. As no problems were identified, later those who did not use the 
equipment were also included. Patients who cannot ingest caffeine or lactose, with 
physical limitations for the exercise test, in use of drugs to treat arrhythmias, who 
were hospitalized in the two months prior to the tests, and patients with ICD who 
had episodes of unstable ventricular arrhythmias in the two months prior to the 
tests were excluded. 
Researchers found no association between caffeine intake and arrhythmia episodes, 
even during treadmill exercise testing. There were also no significant differences 
between caffeine and placebo intake or any indication of increased risk of cardiac 
dysfunction. "In this context, there is no solid evidence to support the common 
orientation of restricting coffee consumption, a result which may change the 
approach to heart failure patients. I stress, however, that the long-term effect has 
not been tested," says Priccila. 
The researcher remarked that the motivation for the study, which is also part of her 
doctoral dissertation, started with the following question: "Do we really need to 
deprive heart failure patients of their consumption of coffee and other sources of 
caffeine? Since coffee is a very popular drink, and the common orientation is to 
restrict its consumption, even without a consensus in the literature of this need, it 
is very useful for society to test this assumption in a well-designed study," she 
says. 
Priccila further notes that this was the first study to test the short-term effect of 
high doses of caffeine in high-risk patients. There have been previous studies, 
mostly performed in the 1980s and 1990s, which tested the effect of caffeine on 
arrhythmia in other populations and with lower caffeine doses, but their results are 
controversial. "Some of the previous studies do not bring important methodological 
information to ensure scientific rigor," she says, exemplifying the lack of details 
related to the randomization of the groups, to the "blindness" of the evaluators and 
participants (which guarantees that neither the patient nor the data collector knows 
the type of treatment given to each one) and the description of losses (participants 
who entered the study, but did not complete the observation period). 
Priccila also recalls that the study followed the validated protocol Consort 
(Consolidated Standards of Reporting Trials), designed to guide the execution and 
writing of clinical trials. "Our work was also quite rigorous over the period of time 
patients had to refrain from ingesting caffeine sources before the beginning of each 
phase of the protocol. This time was seven days longer than the other studies, in an 
attempt to ensure that the observed effect was actually from the caffeine 
administered during the protocol rather than from prior consumption. " 
The researchers also warn that the findings should be interpreted with caution 
because of the relatively small number of patients included and the fact that only 
short-term effects of caffeine have been evaluated. "It would be interesting to test 
this long-term effect, as well as other sources of the substance, such as energy 
drinks that have, in addition to caffeine, other stimulants," says Priccila. 
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